Articles from VedaBio

VedaBio, a pioneering biotechnology company transforming molecular detection, today announced new proof-of-concept data demonstrating sample-to-answer times of under 10 minutes using its integrated, target amplification-free CRISPR-based molecular diagnostics technology. The findings, presented at the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo in Seattle, Washington, highlight the potential of the technology to help overcome longstanding challenges associated with bringing molecular testing closer to patients.

VedaBio, a pioneering biotechnology company transforming molecular detection, today announced the appointment of Valerie Dixon, Chief Financial Officer of Cleveland Diagnostics, as the first independent member of its Board of Directors. Dixon brings two decades of experience advising healthcare and life sciences companies, executives and boards on strategic and financial matters, including mergers and acquisitions, and various financings.

VedaBio, a biotechnology company transforming molecular detection, today announced it has selected UCP Merchant Medicine (UCPMM), a health system management company serving the urgent care channel, to help position its target amplification-free, CRISPR-based molecular diagnostics platform for the urgent care setting. Under the multi-year engagement, UCPMM will work with VedaBio to establish the market expectations, performance benchmarks, training requirements and pricing references to position the platform for success in urgent care, supporting VedaBio’s goal of making it a first-in-class, leading testing platform in the industry.

VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a Series A extension alongside a strategic agreement with Siemens Healthineers. Together, these commitments total up to $25 million for advancing VedaBio’s CRISPR-based product platform. Moreover, it is an important step in validating VedaBio’s vision of leveraging an amplification-free technology to meet critical unmet needs in decentralized molecular diagnostics.

VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, Inc. for the use of select CRISPR-based technologies in diagnostic applications.

VedaBio, a pioneering biotechnology company transforming molecular detection, today announced the appointment of Rachel Jones as Chief Commercial Officer. With over 25 years of experience in molecular diagnostics, Rachel brings a proven track record of successfully commercializing groundbreaking solutions in clinical diagnostics. Her appointment marks a pivotal step as VedaBio advances the development and commercialization of its revolutionary CRISPR-based molecular detection platform.

VedaBio, a pioneering biotechnology company at the forefront of molecular detection, today announced the appointment of Randy Rasmussen, Ph.D., to its Board of Directors. Dr. Rasmussen, a visionary in the molecular diagnostics field with over 30 years of experience, brings deep industry knowledge to VedaBio as the company advances its breakthrough platform and enters the crucial stage of product development. In addition to his board position, Dr. Rasmussen will also serve as an Advisor to the company.

VedaBio, a biotechnology company leading a paradigm shift in molecular detection, today announced the appointment of G. Brett Robb, Ph.D., as Senior Scientific Director and Head of CRISPR Science. With over 16 years of experience in life sciences R&D, Dr. Robb brings extensive expertise in CRISPR-Cas systems, enzyme-based tools, and RNA biology. His appointment marks a significant milestone as VedaBio advances the development and commercialization of its innovative CRISPR-based molecular detection platform.

VedaBio, the biotechnology company leading a paradigm-shift in molecular detection, today announced that Frédéric Sweeney, PhD, has been appointed President and Chief Executive Officer. He previously held the role of Executive Chairman, President and Chief Operating Officer at VedaBio. The company also announced the appointment of industry veteran Maurice Exner, PhD, as Chief Operating Officer.

VedaBio, the biotechnology company leading a paradigm-shift in molecular detection, today announced the formation of its scientific advisory board (SAB) comprised of world class academic and industry experts Rashid Bashir, PhD, Daniel Durocher, PhD, Patrick Hsu, PhD and David Perlin, PhD.

VedaBio, the biotechnology company leading a paradigm-shift in molecular detection, today launched with initial funding of over $40 million backed by lead investor OMX Ventures along with a select group of family offices, including Kleinmuntz Associates. VedaBio has unlocked the true power of CRISPR for molecular detection by developing the CRISPR Cascade, a revolutionary platform born from the intersection of engineering and biology.